- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00103584
Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers
January 11, 2007 updated by: VaxGen
A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of LC16m8, A Modified Vaccinia Vaccine, in Healthy Volunteers
This is a Phase I/II study evaluating the safety and immunogenicity of LC16m8, a modified vaccinia vaccine.
After consent and thorough screening (including safety labs, EKG, and medical history), healthy, previously unvaccinated volunteers between the ages of 18-34 will receive a single vaccination of either LC16m8 or the current US-licensed smallpox vaccine, Dryvax.
Volunteers will be blindly randomized to a treatment group in a 4:1 ratio (4 LC16m8 to 1 Dryvax recipient).
Follow-up clinical evaluations, laboratory testing, EKGs and cardiac assessments will be done at regularly scheduled follow-up visits for 1 year after vaccination.
Study Overview
Study Type
Interventional
Enrollment
150
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University, General Clinical Research Center
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky, Kentucky Clinic
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- St. Louis University, Center for Vaccine Development
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232-2195
- Vanderbilt University Medical Center, General Clinical Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 34 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Able to understand the study and give written informed consent. A signed informed consent must be in place prior to any study procedures being performed.
- Male or female aged 18-34 years old (inclusive; year of birth = 1971-1987).
- No history of smallpox vaccination or evidence of vaccine site scar.
- Willing and able to return for all follow-up visits, study procedures, and blood draws for the duration of the study.
- In good health, as ascertained by medical history, clinical assessment, and baseline (screening) laboratory assessments.
- Negative ELISA for HIV or, if indeterminate, Western blot or other assay confirming that the serostatus does not reflect HIV infection.
- Negative Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) serology.
- Negative urine glucose by urinalysis (UA).
- ALT <1.5 times upper limit of normal.
- Adequate renal function as defined by serum creatinine ≤1.5 mg/dL; urine protein <100 mg/dL, or trace or negative proteinuria by UA, and an estimated creatinine clearance of >55 mL/min. Renal function is measured to ensure that subjects could meet criteria for use of Vistide, should this be needed.
- Hematocrit, hemoglobin, platelets, and white blood cell count (WBC) within normal limits for males and females.
- EKG and EEG (for those being tested) baseline readings within normal limits (these will be read at a central site).
- Willing to refrain from donating blood (other than study-related) throughout the study and for a period of at least 21 days (or until scab separation) after vaccination. In some cases, state laws are more restrictive.
- Negative serum pregnancy test for females at screening and within 2 days prior to vaccination.
- If the volunteer is female and of childbearing potential, she must agree to use effective birth control methods and not become pregnant during the course of the study. A female is considered to have childbearing potential unless post-menopausal or surgically sterilized. Effective birth control methods include licensed, approved hormonal methods such as pills, patch, injection, or implant.
Exclusion Criteria:
- Planning to move within 52 weeks from the time of vaccination.
- Known allergy to any materials used in this study or components of the vaccines, which may include erythromycin, streptomycin, chlortetracycline, polymyxin B, neomycin, phenol, glycerin, Vaccinia Immune Globulin (VIG), immunoglobulin, blood products containing immunoglobulin preparations, cidofovir, probenecid, and/or bandage adhesive tape.
- Pregnant or breastfeeding, or have close contact** with someone who is pregnant or breastfeeding.
- Active or past history of atopic dermatitis or eczema, or close contact** with someone with active or past history of atopic dermatitis or eczema.
- Presence of (or close contact** or sharing a household with) a skin condition with extensive breaks in the skin such as burns, impetigo, contact dermatitis, or zoster (shingles) not likely to heal by the day of vaccination.
- Darier's disease or close contact** with Darier's disease.
- Immunosuppression (including HIV), or close contact** with an immunosuppressed individual.
- Using immunosuppressive medications, in eye drops, by mouth, or topically (corticosteroid nasal sprays and inhalers are permissible at low doses after discussion with VaxGen Medical Monitor).
- Close contact** with children under 1 year old.
- Active or past malignancy with the exception of non-metastatic skin cancers.
- History of exuberant keloid formation.*
- Known cardiac disease or three or more cardiac risk factors (high blood pressure, diabetes mellitus, smoking, hypercholesterolemia, heart disease at age 50 or earlier in a first-degree relative, or obesity [defined as Body Mass Index (BMI)>30]).
- Currently under treatment for high blood pressure.
- History of solid organ or bone marrow transplantation.
- Evidence of immunosuppression or autoimmune disease, cardiac disease, renal disease, splenectomy, or unstable medical condition as determined by baseline medical history, physical assessment, or laboratory assessments.
- Neurological or psychological condition that may place volunteer at heightened risk from vaccination.
- Psychiatric condition that precludes compliance with the protocol.
- Received or plan to receive live vaccines 30 days before or after study vaccination.
- Received or plan to receive subunit or killed vaccines 14 days before or after study vaccination.
- Received or plan to receive immunoglobulin or other blood products 60 days prior to HIV screening or study vaccination.
- Received or plan to receive experimental drugs/vaccines 30 days before study vaccination or prior to study completion.
- Received or plan to receive systemic immunosuppressive therapy or radiation therapy 30 days before study vaccination or prior to study completion.
Served in military conflicts and received smallpox vaccination, or military service prior to 1989.
As determined by the Principal Investigator (PI).
- Close contact = frequent physical contact or sharing linen/clothing.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Safety and immunogenicity
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Marc Gurwith, MD, JD, VaxGen
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2004
Study Completion
July 1, 2006
Study Registration Dates
First Submitted
February 10, 2005
First Submitted That Met QC Criteria
February 10, 2005
First Posted (ESTIMATE)
February 11, 2005
Study Record Updates
Last Update Posted (ESTIMATE)
January 15, 2007
Last Update Submitted That Met QC Criteria
January 11, 2007
Last Verified
January 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VAX012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smallpox
-
National Institute of Allergy and Infectious Diseases...CompletedVariola Major (Smallpox)United States
-
Emergent BioSolutionsCenters for Disease Control and PreventionEnrolling by invitationComplication of Smallpox Vaccination
-
Emergent BioSolutionsCenters for Disease Control and PreventionCompletedSmallpox Vaccine Adverse ReactionUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
Emergent BioSolutionsCompletedSmallpox Vaccine Adverse ReactionCanada
-
National Institute of Allergy and Infectious Diseases...Completed
-
Emergent BioSolutionsCompleted
-
SIGA TechnologiesUnited States Department of DefenseCompleted
-
SIGA TechnologiesUnited States Department of DefenseCompletedSmallpoxUnited States
-
SIGA TechnologiesPPD; Biomedical Advanced Research and Development AuthorityCompleted
Clinical Trials on LC16m8 Smallpox Vaccine
-
National Institute of Allergy and Infectious Diseases...Completed
-
Sanofi Pasteur, a Sanofi CompanyTerminatedHIV Infections | SmallpoxUnited States
-
Sanofi Pasteur, a Sanofi CompanyWithdrawnAtopic Dermatitis | SmallpoxUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
Ivan LitvinovTerminatedBasal Cell Carcinoma | Squamous Cell Carcinoma | Non-melanoma Skin CancerCanada
-
Seoul National University HospitalHK inno.N CorporationCompleted
-
Federal Budgetary Research Institution State Research...CompletedSmallpox | Monkeypox | Cowpox | Vaccinia Virus InfectionRussian Federation
-
Seoul National University HospitalHK inno.N CorporationCompleted
-
Emergent BioSolutionsCompleted